Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)

Inclusion Criteria:

Patient diagnosed with MS according to McDonald criteria
Age 18-65
Have a RR disease course
Have EDSS scores 0-5.5
Have a disease duration <20 years
Sub-optimal response to Interferon beta-1a I.M. (Avonex®) while being on therapy for at least 6 months defined as:
presence of a documented relapse within the last 12 months
or the presence of at least one enhancing T1 Gd lesion on an MRI performed within previous 3 months
Signed informed consent
Normal kidney functioning (creatinine clearance >59)
None of the exclusion criteria

Exclusion Criteria:

Presence of relapse or steroid treatment within 60 days prior to study enrollment
Presence of neutralizing antibodies to IFNβ-1a I.M. prior to study enrollment
Presence of optic neuritis within less than 6 months prior to study enrollment
Diagnosis of osteoporosis (T score ≥2.5 SD)
Women who are pregnant, lactating or of childbearing age who do not consent to approved contraceptive use during the study.
Abnormal blood tests, performed during the screening visit including: hepatitis B or hepatitis C, ALT or AST greater than two times the upper limit of normal, abnormal glucose fasting levels or already known diabetes
History of depression while on IFNβ-1a I.M.